Cui, J., Wang, L., Cao, J., Quan, M., Li, W., Zhang, M., Li, D., Lu, Y., Qu, X., Wu, J., Yao, G., Li, Z. (2026). Preliminary results of ALTER-PA-001 trial: A multicenter, open-label, randomized, phase II trial of anlotinib and benmelstobart in combination with AG versus AG as first-line treatment for metastatic pancreatic cancer.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.719